News & Partnering
Learn more about Imvax
For more detail on our progress, behind the scenes at Imvax, or opportunities to collaborate with us to advance the future of immunotherapy, dive in below.
Press releases
Imvax Presents Preclinical Data at SITC 2022 Supporting Mechanism of Action and Anti-tumor Activity of its Immunotherapy Platform Across Multiple Tumor Types
– Features of immunogenic cell death linked to the platform’s mechanism of action were associated with immune cell stimulation in lymph nodes – – Platform found to... Read more
Imvax to Present New Data on Tumor-Derived Immunotherapy Platform at 2022 SITC Meeting
PHILADELPHIA (October 6, 2022) — Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, today announced two poster presentations at the 2022 Society for Immunotherapy of... Read more
Imvax Presents New Data on Personalized Whole-Tumor Derived Immunotherapeutic Platform at 2022 International Cancer Immunotherapy Conference
– Immune responses observed in endometrial cancer and glioblastoma models, complementing prior clinical success in glioblastoma and supporting further development of IEC-001 for the treatment of endometrial... Read more
Imvax to Present New Data on Tumor-Derived Immunotherapy Platform at 2022 International Cancer Immunotherapy Conference
PHILADELPHIA (September 21, 2022) — Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, today announced a poster presentation at the 2022 International Cancer Immunotherapy Conference... Read more
Partnering with us
At Imvax, we know that making transformational therapies a reality takes many minds and different technologies working together. We welcome expressions of interest in collaborating to deliver a new generation of immunotherapies. We are a passionate, patient-focused, data-driven platform company.